Physician profile
Carson Turner
NPI 1467676064
$3,752.48
in general payments reported to CMS, 2019-2025
25 companies · $868 in 2025
The $868 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $246 · 2021: $385 · 2022: $628 · 2023: $457 · 2024: $689 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,141.42 | 2019-2024 | Mitraclip, Xience V, Xience Alpine |
| Boston Scientific Corporation | $567.69 | 2019-2025 | General - Tachy, Rotablator Rotational Atherectomy System Console Kit, Lux-Dx Insertable Cardiac Monitor |
| Biotronik INC. | $369.72 | 2024-2025 | Acticor 7 Vr-T Dx, Biomonitor, Amvia Edge |
| Medtronic Vascular, INC. | $264.27 | 2019-2020 | |
| Abiomed | $257.18 | 2019-2024 | |
| Medtronic, INC. | $216.41 | 2021-2022 | |
| Novo Nordisk INC | $135.04 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $121.26 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $115.16 | 2022-2025 | |
| Pfizer INC. | $100.41 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $76.91 | 2019-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $59.72 | 2025 | Onpattro |
| Chiesi USA, INC. | $48.13 | 2023 | Kengreal |
| Merck Sharp & Dohme LLC | $44.81 | 2025 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $43.14 | 2019-2024 | Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $35.80 | 2024-2025 | Camzyos |
| Shockwave Medical, INC | $25.68 | 2025 | |
| Cvrx, INC. | $20.54 | 2024 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $18.61 | 2024 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $16.20 | 2025 | Evkeeza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.14 | 2023 | Lifevest |
| Agepha Pharma Fz LLC | $15.45 | 2025 | Lodoco |
| Terumo Medical Corporation | $14.96 | 2021 | |
| Teleflex LLC | $14.22 | 2020 | |
| Cleerly, INC. | $13.61 | 2024 | Cleerly Ischemia, Cleerly Labs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carson Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.